Navigation Links
ViroPharma Announces Presentation of Cinryze(TM) Data in Acute Treatment of Hereditary Angioedema
Date:11/12/2008

lso reported visiting an average of 4.4 different physicians before receiving an accurate diagnosis of HAE. In addition, survey participants had an average of two immediate and two extended family members that had been diagnosed with HAE, but only 48 percent of their immediate family members and 26 percent of their extended family members had been tested for HAE.

"Accurate, timely diagnosis of HAE patients continues to be a challenge, and despite the fact that HAE is a hereditary disorder, testing family members is not common practice; a consensus statement may lead to improved and earlier diagnosis of patients with HAE," said Timothy Craig, DO, professor of medicine, Penn State University, who co-presented the survey data. "These findings indicate that testing family members for HAE should be a primary concern for those caring for patients with the disorder, and patients should be alerted to the need for screening of their family members."

About Cinryze C1 Inhibitor (human)

Cinryze is a highly purified, pasteurized and nanofiltered plasma-derived C1 inhibitor product that has been approved by FDA for routine prophylaxis against angioedema attacks in adolescent and adult patients with HAE. C1 inhibitor therapy has been used acutely for more than 30 years in Europe to treat patients with C1 inhibitor deficiency. Cinryze has not been approved for acute treatment in the United States or any other jurisdiction.

Cinryze has been well tolerated. The most common adverse reactions observed have been upper respiratory infection, sinusitis, rash and headache. No drug-related serious adverse events (SAEs) have been observed in clinical trials. Severe hypersensitivity reactions may occur. Thrombotic events have occurred in patients receiving high dose off-label C1 inhibitor therapy well above the approved treatment dosage regimen. With any blood or plasma derived product, there may be a risk of transmission of infectious agents, e.g. viruses and, the
'/>"/>

SOURCE ViroPharma Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. ViroPharma Incorporated Completes Acquisition of Lev Pharmaceuticals
2. ViroPharma Announces Completion of Enrollment in Phase 3 Study of Maribavir in Stem Cell Transplant Patients
3. ViroPharma Announces Discontinuation of HCV-796 Development
4. ViroPharma to Release 2008 First Quarter Financial Results on April 30, 2008
5. ViroPharma To Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
6. ViroPharma to Present at the Natixis Bleichroeder Conference
7. ViroPharma to Present at Three Upcoming Healthcare Conferences
8. Alba Therapeutics Announces Enrollment of Its First European Patient in Global Phase IIb Study of Larazotide Acetate for Treatment of Active Celiac Disease
9. Raptor Pharmaceuticals Corp. Announces Positive Phase IIa Clinical Study Results for Convivia(TM) Program
10. Anesiva Announces Adlea ACTIVE-1 Phase 3 Clinical Results, Ceasing of Zingo Commercial Operations and Restructuring
11. Diagenic Announces Launch of First Breast Cancer Gene-Expression Blood Test
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... --Research and Markets ( http://www.researchandmarkets.com/research/942kh3/micro_market ) ... Market Monitor: North American Dermatology Diagnostic Devices Market" ... http://photos.prnewswire.com/prnh/20130307/600769 Cosmetic surgeries ... resulted in fueling the overall demand of the ... these dermatology devices is to assist in identifying ...
(Date:12/19/2014)... , Dec. 18, 2014  Decision Resources Group ... the United States will increase to a ... be primarily driven by expansion in the large direct ... devices will be increasingly adopted due to the advantages ... Other key findings from Decision Resources Group,s coverage ...
(Date:12/19/2014)... , Dec. 18, 2014  RESMED INC. (NYSE: ... second quarter of fiscal year 2015 results on Thursday, January ... A press release with ResMed,s results will be issued after ... a webcast to discuss operating results and future outlook. ... p.m. US Pacific Time and the live webcast of the ...
Breaking Medicine Technology:Micro Market Monitor: North American Dermatology Diagnostic Devices Market 2Micro Market Monitor: North American Dermatology Diagnostic Devices Market 3U.S. Laparoscopic Device Market Will Reach Over $4.3 Billion by 2023 2U.S. Laparoscopic Device Market Will Reach Over $4.3 Billion by 2023 3ResMed To Announce Second Quarter 2015 Results 2
... Index (BMI) Rebound Age, Can Predict Heart Disease and Calls for ... Children,s ... The results from the newest study,in a continuum of research on childhood ... reason for pediatricians to begin,measuring and monitoring body mass index (BMI) in ...
... Tissue Oncology, Society held in Seattle, Washington demonstrates clinical ... single agent in patients with ... chemo-insensitive sarcomas, NEW YORK, Nov. ... preliminary data demonstrating the,tolerability and clinical activity of KRX-0401 (perifosine) in ...
Cached Medicine Technology:New Risk Factor for Heart Disease Identified in Very Young Children, According to Study at American Heart Association Scientific Sessions 2New Risk Factor for Heart Disease Identified in Very Young Children, According to Study at American Heart Association Scientific Sessions 3Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma 2Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma 3Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma 4Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma 5Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma 6
(Date:12/19/2014)... These vanadium reserves are mostly found in ... tons of vanadium were produced globally in 2013, up ... at 6.7% AAGR during the period from 2001 to ... the largest consumer, accounted for more than 90% of ... and the chemical industry. , View Full Report at ...
(Date:12/19/2014)... FRIDAY, Dec. 19, 2014 (HealthDay News) -- New research warns parents ... young lives at risk. Nearly half of teen drivers killed ... that were at least 11 years old and often lacked important ... Eighty-two percent of teen drivers killed in crashes were in ... six to 10 years old, 31 percent were in cars 11 ...
(Date:12/19/2014)... FRIDAY, Dec. 19, 2014 (HealthDay News) -- Injectable drug ... double the suicide attempt rate of other substance users, ... use is associated with the risk of suicide attempt ... the University of Montreal, said in a university news ... users. We wanted to know who among substance users ...
(Date:12/19/2014)... Raleigh, NC (PRWEB) December 19, 2014 Surviving ... asbestos and EPA information indicates that these pipes can leach ... to go to the full story on the Surviving ... to the erosion of natural asbestos deposits, decaying water mains ... in drinking water. , To protect consumers from ...
(Date:12/19/2014)... B. E. Smith, the only full-service leadership solutions ... to lead a national chief financial officer search ... top executive search firm in the healthcare industry, B. ... executives into organizations. , Johnson Memorial Hospital is ... the residents of Johnson County and the surrounding areas. ...
Breaking Medicine News(10 mins):Health News:Marketresearchreports.biz: Global Vanadium Usage Increased at AAGR of 6.7% between 2001 and 2013 2Health News:Marketresearchreports.biz: Global Vanadium Usage Increased at AAGR of 6.7% between 2001 and 2013 3Health News:Older Cars a Bad Choice for Younger Drivers 2Health News:Cocaine, Amphetamines May Up Injection Drug Users' Suicide Risk 2Health News:Surviving Mesothelioma Warns of Potential Mesothelioma Risk from Cement Water Pipes 2Health News:Johnson Memorial Hospital Retains B. E. Smith to Recruit New Chief Financial Officer 2Health News:Johnson Memorial Hospital Retains B. E. Smith to Recruit New Chief Financial Officer 3
... on knowing when you,re ready to drive again , , WEDNESDAY, ... get behind the wheel again after orthopedic surgery or injury, but ... turning the key. , Orthopedic surgeons weigh in on the issue ... Joint Surgery . , "Deciding when a patient can return ...
... (OTC Pink Sheets: SNDY ) is pleased to announce that ... by over 10% compared to the same time period for 2007. ... $28,509 for the same month last year. This marks the second ... of October. , , The Mammo ...
... Dec. 10 GeneGo, Inc., a leading,provider of software ... ,today announced that A*STAR,s Singapore Immunology Network (SIgN) has ... will have access,to GeneGo,s MetaCore, training and advanced support. ... all SIgN researchers. , ...
... Three Skilled Nursing Facilities , , ... intense 18-month selection process, a proven commitment to clinical ... records (EMR) throughout Metropolitan Jewish Health System,s (Metropolitan) skilled ... Metropolitan, a nationally recognized nonprofit organization, operates Metropolitan ...
... Services, Goodwill, , , ... MDZ ), a leading provider of products and services ... 2008 performance. , Based on preliminary information, MDS expects ... $1,210 million to $1,220 million and adjusted EBITDA in the range ...
... While They,re Still Healthy Enough to Qualify , ... you,ve put off getting long term care insurance, should you ... health plan? "I wouldn,t advise it," says Denise Gott, Chairman ... of the nation,s most experienced long term care insurance agencies. ...
Cached Medicine News:Health News:Returning to the Road Tricky After Injury 2Health News:Solos Endoscopy, Inc. Increases Sales Revenue for October 2008 by Over 10% as Compared to Last Year 2Health News:A*STAR's Singapore Immunology Network Is the First GeneGo Center of Excellence in Asia 2Health News:Metropolitan Jewish Health System Awards Electronic Medical Records Contract to SigmaCare(R) 2Health News:Metropolitan Jewish Health System Awards Electronic Medical Records Contract to SigmaCare(R) 3Health News:MDS Provides Update on Fiscal 2008 Performance 2Health News:MDS Provides Update on Fiscal 2008 Performance 3Health News:MDS Provides Update on Fiscal 2008 Performance 4Health News:Obama Health Plan Not Likely to Embrace Long Term Care, Industry Leader Says 2
... available in oxygen, air, heliox and CO 2 . ... to best suit your application. With color coded labels ... Amvex Flowmeter is a user friendly device., ,For ... Take-Off add PT to the end of the part ...
... flowmeters, available in oxygen, air, heliox and CO 2 ... calibrations to best suit your application. With color coded ... the Amvex Flowmeter is a user friendly device., ... Power Take-Off add PT to the end of the ...
... a complete line of flowmeters, available in oxygen, air, ... in a variety of calibrations to best suit your ... the gas in use, the Amvex Flowmeter is a ... U with I. For Power Take-Off add PT to ...
0-3.5 LPM Oxygen Flowmeter with Ohmeda male inlet...
Medicine Products: